Table 2.
Patient data and outcome
| Parameter | Disease-free survival [months] | Overall survival [months] | |||||
|---|---|---|---|---|---|---|---|
| Mean ± SE | Log-rank test | HR (95 % CI) | Mean ± SE | Log-rank test | HR (95 % CI) | ||
| Age Range, 39–92 years Median, 74 years |
<74 years(1) (n = 21)(2)
≥74 years (n = 20)(2) |
26.0 ± 3.0 38.3 ± 3.7 |
0.3156 | 0.60 (0.20, 1.62) | 35.4 ± 2.0 60.7 ± 5.4 |
0.4076 | 1.62 (0.51, 5.48)(5) |
| Tumor size Range, 5–85 mm Median, 30 mm |
≤50 mm(1) (n = 34)(2)
>50 mm (n = 6)(2) |
34.7 ± 2.9 6.0 ± 0.0 |
0.7194 | 1.31 (0.20, 4.77) | 58.9 ± 3.6 40.7 ± 8.2 |
0.3578 | 2.03 (0.31, 8.00) |
| ≤20 mm(1) (n = 10)(2)
>20 mm (n = 30)(2) |
34.1 ± 3.9 31.6 ± 3.4 |
0.1505 | 2.82 (0.79, 17.97) | 39.0±– 55.2 ± 4.3 |
0.2294 | 3.28 (0.63, 60.25) | |
| Grading | G1(1) (n = 10)(2) | 29.2 ± 4.4 | 0.9536(3) | 69.4 ± 8.7 | 0.4802(3) | ||
| G2 (n = 23)(2) | 34.5 ± 3.8 | 0.7818 | 1.16 (0.38, 4.30) | 45.4 ± 2.9 | 0.2424 | 2.60 (0.61, 17.77) | |
| G3 (n = 8)(2) | 10.3 ± 0.7 | 0.9856 | 0.99 (0.20, 4.49) | 57.1 ± 9.6 | 0.3791 | 2.22 (0.37; 16.93) | |
| Ki67% | ≤20(1) (n = 19)(2) | 30.2 ± 4.1 | 0.0604 | 57.3 ± 5.6 | 0.1951 | ||
| >20 (n = 22)(2) | 27.7 ± 2.2 | 0.51 (0.19, 1.44) | 64.2 ± 4.7 | 1.49 (0.46, 5.69) | |||
| PIK3CA | No mutation (n = 18)(2) | 34.4 ± 3.8 | 0.9397 | 60.0 ± 5.0 | 0.2413 | ||
| Mutation (n = 18)(2) | 13.5 ± 1.1 | 0.96 (0.32, 2.68)(5) | 41.1 ± 3.4 | 2.16 (0.57, 8.82) | |||
| No mutation (n = 24)(2) | 35.1 ± 3.4 | 0.5564 | 59.9 ± 4.3 | 0.1447 | |||
| H1047R mutation (n = 12)(2) | 13.2 ± 1.3 | 1.38 (0.43, 3.96)(5) | 38.4 ± 4.6 | 2.59 (0.63, 9.96) | |||
| Surgery | BCT(1) (n = 23)(2) | 28.0 ± 2.8 | 0.7733 | 61.6 ± 4.2 | 0.1909 | ||
| Mastectomy (n = 18)(2) | 35.9 ± 4.5 | 0.86 (0.29, 2.33) | 55.9 ± 6.8 | 2.12 (0.67, 7.20) | |||
| Margin <5 mm (n = 16)(2) | 27.6 ± 3.4 | 0.7707 | 44.8 ± 2.5 | 0.4963 | |||
| Margin ≥5 mm (n = 22)(2) | 32.3 ± 5.7 | 1.18 (0.38, 3.54) | 47.2 ± 4.7 | 1.73 (0.32, 9.42) | |||
| Adjuvant therapy | None(1) (n = 22)(2) | 31.0 ± 3.8 | 0.0507(3) | 57.6 ± 5.3 | 0.0715(3) | ||
| Radiotherapy (n = 10)(2) | 14.0 ± 1.5 | 0.1715 | 0.62 (0.14, 1.97) | 57.1 ± 9.1 | 0.4120 | 0.82 (0.18, 2.85) | |
| Radio−/chemoth. (n = 7)(2) | N.E. | 0.0154 | N.E. | N.E. | 0.0790 | N.E. | |
(1) = Reference category chosen for the Cox PH model, (2) = case number, (3) = global. Median survival was calculated according to the Kaplan-Meier method. Calculation of median survival and its upper or lower confidence interval limits or SE were not always possible. These cases are indicated as (–). There were no events in the Radio−/Chemotherapy group (N.E.). In some models, the Cox PH assumption may not be met (5). For variables with 3 groups, a global log-rank test was performed as well as pairwise comparisons with a reference
CI confidence interval, HR hazard ratio, BCT breast-conserving therapy, SE standard error